Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

Gilead’s John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

Non-profit calls to revoke Sovaldi’s European patent

Doctors of the World says Gilead is “abusing its patent” to impose unsustainable prices

- PMLiVE

Gilead to open London headquarters

Mayor Boris Johnson makes announcement as part of trip to Boston, US

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

EU approval for Gilead’s hep C combo Harvoni

Another boost for the company’s fast-growing Sovaldi franchise

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links